Healthcare

Growth Indicators for Technology-enabled Drug Discovery Updated Research Available

Innovative Business Models across the TEDD Landscape Support the Emergence of AI-powered Therapeutics Providers

INDUSTRY
Healthcare

RELEASE DATE
22-Jun-2023
REGION
North America
DELIVERABLE TYPE
Market Research

RESEARCH CODE
PED7-01-00-00-00
SKU
HC03679-NA-MT_27807
Yes
SHARE

Growth Indicators for Technology-enabled Drug Discovery
Published on: 22-Jun-2023 | SKU: HC03679-NA-MT_27807

Need more details?

$2,450.00

$1,837.50 save 25 %

DownloadLink
Need more details?

As the industry continues its innovation spree across novel small and large molecule therapies, such as RNA targeted small molecules, cell and gene therapies (CGT), and mRNA therapies, it is imperative for pharma sponsors to pursue partnerships to gain technology access, database generation and analysis, and pre-clinical and clinical research. Furthermore, the COVID-19 pandemic led to a serious disruption in pharma innovation, with companies not only looking for novel cures but also trying to leverage or repurpose existing therapies.

As a result of so many constant changes and disruptions, the industry is transforming, taking a convergence approach in which vendors are working together across all facets of drug discovery and development. The entire drug development ecosystem is expanding, with reliance on pure-play technology vendors, AI platform providers, academia and research centers, and outsourcing vendors such as CROs that can configure AI algorithms into their pre-clinical and clinical research portfolios.

Tech-enabled drug discovery (TEDD) vendors are successfully integrating into the pharma value chain by re-establishing their role as digital biotechnology companies that develop in-house therapeutic pipelines with specific focus on oncology, rare diseases, immunology, and anti-aging. Moreover, these TEDD vendors are focusing on both in-house capabilities (AI-powered therapeutics) and on providing platform-based and project-based partnerships with pharma players to support their therapeutic pipeline development.

AI integration into drug discovery remains on an upward trend, increasing almost 40% as of 2022, with a shift in focus from customized insights to intelligent solutions. The increasing volume and veracity of clinical and research data compels traditional providers to leverage enabling tools and technologies to provide fast, rational data-driven drug discovery solutions. For effective drug discovery of novel molecules, companies require uninterrupted access to databases (e.g., translational, molecular, longitudinal, foundational). TEDD vendors provide access to these databases and support de novo drug design owing to their robust computational capabilities. From data integration, analysis, and predictive modeling to real-time monitoring and quality control, AI-embedded applications across dry and wet labs can improve experimentations tied to not only cost and time efficiency, but also optimized workflows

This research service provides an overview of the global TEDD landscape, including analysis related to pharma industry participants and the leading drivers, restraints, and trends shaping the uptake of innovative technologies and platforms. The report takes a deep dive into the ongoing dynamics tied to technology implementation, from data collection to wet labs, that support a quicker, easier, and enhanced drug discovery process in much less time. Analysis includes insights into the overall funding scenario among key vendors and the geopolitical and macro-economic factors influencing that scenario. Based on ongoing industry trends, the analysis shortlists the unique business models that AI vendors in this space use to build in-house pipelines or to function as a strategic partner to pharma companies in support of their novel pipelines. In consideration of the business models and subsequent partnership models, the report benchmarks the top 5 competitors based on their proprietary pipelines (early to late stage), chemical and biological data capabilities, and ongoing partnerships. Also, detailed profiles of emerging and start-up TEDD vendors, with a focus on target discovery, validation, candidate discovery, lead identification and optimization, and preclinical research, amongst other areas are included.

Author: Aarti Siddhesh Chitale

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Technology-enabled Drug Discovery (TEDD) Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Scope of Analysis

Definitions

TEDD Market Overview

Key Market Challenges Impacting Drug Discovery

Evolving TEDD Landscape

TEDD Value Proposition

Next-generation Trends Dominating the TEDD Landscape

Key Drug iscovery Activities with AI-embedded pplications

Growth Drivers

Growth Restraints

Evolving Vendor Ecosystem

Market Snapshot

AI Vendor Focus by Drug Discovery Stage

Market Snapshot—Large Molecules

Market Snapshot—Small Molecules

Types of Funding across TEDD

Types of Funding across TEDD (continued)

Funding Scenario by Funding Value

TEDD Market Funding Outlook

Key Competitors by Region

Market Landscape—Business Models

Types of Service Provider Based on Business Models

Key Competitors Based on Type of Service Provider

Competitive Benchmarking—Parameters and Rating Considerations

Competitive Benchmarking—Leading TEDD Vendors

Vendor Spotlight—Recursion

Recursion—Competitive Assessment

Industry Use Case and Analyst Perspective

Vendor Spotlight—AbCellera Biologics

AbCellera Biologics—Competitive Assessment

Industry Use Case and Analyst Perspective

Vendor Spotlight—Exscientia

Exscientia—Competitive Assessment

Industry Use Case and Analyst Perspective

Vendor Spotlight—Insitro

Insitro—Competitive Assessment

Industry Use Case and Analyst Perspective

Vendor Spotlight—Schrödinger, Inc.

Schrödinger—Competitive Assessment

Industry Use Case and Analyst Perspective

Vendor Spotlight—Peptilogics

Industry Use Case and Analyst Perspective

Vendor Spotlight—Evozyne

Industry Use Case and Analyst Perspective

Vendor Spotlight—Iktos

Industry Use Case and Analyst Perspective

Vendor Spotlight—Neumora Therapeutics

Industry Use Case and Analyst Perspective

Vendor Spotlight—BioAge Labs

Industry Use Case and Analyst Perspective

Growth Opportunity 1: Generative AI and Large Language Models (LLM)

Growth Opportunity 1: Generative AI and LLM (continued)

Growth Opportunity 2: Protein/Peptide Therapeutics Development Using AI

Growth Opportunity 2: Protein/Peptide Therapeutics Development Using AI (continued)

Growth Opportunity 3: Foundational Models for Cell and Gene Therapy (CGT) R&D

Growth Opportunity 3: Foundational Models for CGT R&D (continued)

List of Exhibits

Legal Disclaimer

List of Figures
  • TEDD Market: Growth Drivers, Global, 2023-2028
  • TEDD Market: Growth Restraints, Global, 2023-2028

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

17 Nov 2026   |   Global   |   Frost Radar

Frost Radar™: Quantum-Grade Sensor Technology Ecosystem for Healthcare Applications, 2026

Quantum-grade sensors are advancing healthcare by leveraging quantum phenomena to enable highly sensitive, precise, and non-invasive measurements of biological signals and physiological parameters. These innovations enhance diagnostic accuracy, disease monitoring, brain activity measurement, and ear...

16 Nov 2026   |   North America   |   Frost Radar

Frost Radar™: Healthcare Data Interoperability Platforms and Integration Engines in North America, 2026

This Frost Radar™ analyzes the healthcare data platform and integration engine vendors that enable healthcare organization to improve the exchange, utilization, contextualization, and management of clinical, operational, financial, and administrative data. Data issues, AI adoption, and solution gove...

03 Nov 2026   |   North America   |   Market Research

Enterprise Imaging Market, United States, 2025–2030

Enterprise imaging is no longer a technology upgrade. It is becoming the operating model for imaging across the provider organization, and the next investment cycle will decide which vendors lead it. This study gives vendors, ecosystem partners, and provider leaders a 360-degree view of that shift, ...

02 Nov 2026   |   Global   |   Market Research

Continuous Glucose Monitoring Market, Global, 2026

The global continuous glucose monitoring (CGM) market is undergoing a fundamental transformation as the technology evolves from a prescription-led glucose monitoring device into an AI-connected metabolic intelligence ecosystem. Market expansion is increasingly driven by the emergence of over-the-cou...

28 Oct 2026   |   Global   |   Frost Radar

Frost Radar™: Health Monitoring Wearable Solutions, 2026

The health monitoring wearables industry is undergoing a profound transformation as competitive advantage shifts from device hardware to integrated digital health ecosystems. Market leaders are differentiating through clinically validated health insights, longitudinal data platforms, AI-enabled anal...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.